{"url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1895765/", "query": "oral chelation heart disease", "actual-search-type": "n", "expected-search-type": "a", "contents": "<?xml version=\"1.0\" encoding=\"utf-8\"?>\n<!DOCTYPE html PUBLIC \"-//W3C//DTD XHTML 1.0 Transitional//EN\" \"http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd\">\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xml:lang=\"en\" lang=\"en\">\n    \n    <head><meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n        <!-- AppResources meta begin -->\n        <script type=\"text/javascript\">var ncbi_startTime = new Date();</script>\n        <!-- AppResources meta end -->\n        \n        <!-- TemplateResources meta begin -->\n        <meta name=\"paf_template\" content=\"\" />\n\n        <!-- TemplateResources meta end -->\n        \n        <!-- Logger begin -->\n        <meta name=\"ncbi_db\" content=\"pmc\" /><meta name=\"ncbi_pdid\" content=\"article\" /><meta name=\"ncbi_acc\" content=\"\" /><meta name=\"ncbi_domain\" content=\"blood\" /><meta name=\"ncbi_report\" content=\"record\" /><meta name=\"ncbi_type\" content=\"fulltext\" /><meta name=\"ncbi_objectid\" content=\"\" /><meta name=\"ncbi_pcid\" content=\"/articles/PMC1895765/\" /><meta name=\"ncbi_app\" content=\"pmc\" />\n        <!-- Logger end -->\n        \n        <title>Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions</title>\n        \n        <!-- AppResources external_resources begin -->\n        <link rel=\"stylesheet\" href=\"/core/jig/1.14.8/css/jig.min.css\" /><script type=\"text/javascript\" src=\"/core/jig/1.14.8/js/jig.min.js\"></script>\n\n        <!-- AppResources external_resources end -->\n        \n        <!-- Page meta begin -->\n        <meta name=\"robots\" content=\"INDEX,NOFOLLOW,NOARCHIVE\" /><link rel=\"canonical\" href=\"/pmc/articles/PMC1895765/\" /><link rel=\"schema.DC\" href=\"http://purl.org/DC/elements/1.0/\" /><meta name=\"citation_journal_title\" content=\"Blood\" /><meta name=\"citation_title\" content=\"Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions\" /><meta name=\"citation_authors\" content=\"Ellis J. Neufeld\" /><meta name=\"citation_date\" content=\"1 May 2006\" /><meta name=\"citation_issue\" content=\"9\" /><meta name=\"citation_volume\" content=\"107\" /><meta name=\"citation_firstpage\" content=\"3436\" /><meta name=\"citation_doi\" content=\"10.1182/blood-2006-02-002394\" /><meta name=\"citation_abstract_html_url\" content=\"/pmc/articles/PMC1895765/?report=abstract\" /><meta name=\"citation_pmid\" content=\"16627763\" /><meta name=\"DC.Title\" content=\"Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions\" /><meta name=\"DC.Type\" content=\"Text\" /><meta name=\"DC.Publisher\" content=\"American Society of Hematology\" /><meta name=\"DC.Contributor\" content=\"Ellis J. Neufeld\" /><meta name=\"DC.Date\" content=\"2006 May 1\" /><meta name=\"DC.Identifier\" content=\"10.1182/blood-2006-02-002394\" /><meta name=\"DC.Language\" content=\"en\" /><meta property=\"og:title\" content=\"Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions\" /><meta property=\"og:type\" content=\"article\" /><meta property=\"og:description\" content=\"For nearly 30 years, patients with transfusional iron overload have depended on nightly deferoxamine infusions for iron chelation. Despite dramatic gains in life expectancy in the deferoxamine era for patients with transfusion-dependent anemias, the leading ...\" /><meta property=\"og:url\" content=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1895765/\" /><meta property=\"og:site_name\" content=\"PubMed Central (PMC)\" /><meta property=\"og:image\" content=\"https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-logo-share.png\" /><meta name=\"twitter:card\" content=\"summary\" /><meta name=\"twitter:site\" content=\"@ncbi\" /><link rel=\"stylesheet\" href=\"/corehtml/pmc/css/3.6/pmc.min.css\" type=\"text/css\" /><link rel=\"stylesheet\" href=\"/corehtml/pmc/css/3.6/pmc_extras_prnt.min.css\" type=\"text/css\" media=\"print\" /><script type=\"text/javascript\" src=\"/corehtml/pmc/js/common.min.js\">//</script><script type=\"text/javascript\" src=\"/corehtml/pmc/js/NcbiTagServer.min.js\">//</script><meta name=\"citationexporter\" content=\"backend:'/pmc/utils/ctxp/'\" /><script type=\"text/javascript\" src=\"/corehtml/pmc/ctxp/jquery.citationexporter.js\">//</script><link rel=\"stylesheet\" href=\"/corehtml/pmc/ctxp/citationexporter.css\" type=\"text/css\" /><script type=\"text/javascript\" src=\"/core/mathjax/2.6.1/MathJax.js?config=/corehtml/pmc/js/mathjax-config-classic.3.4.js\"></script><script type=\"text/javascript\" src=\"/corehtml/pmc/js/large-obj-scrollbars.min.js\"></script><script type=\"text/javascript\">window.name=\"mainwindow\";</script><style type=\"text/css\">.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-blood.gif);background-size: auto, contain}</style><style type=\"text/css\">.print-view{display:block}</style><style type=\"text/css\">\n        div.pmc_para_cit li.highlight,\n        div.pmc_para_cit li.highlight .one_line_source\n        { background: #E0E0E0; }\n        a.bibr.highlight { background: #E0E0E0; } \n      </style><meta name=\"cited_in_systematic_reviews\" content=\"\" /><link rel=\"alternate\" type=\"application/epub+zip\" href=\"/pmc/articles/PMC1895765/epub/\" />\n\n        <!-- Page meta end -->\n    <link rel=\"shortcut icon\" href=\"//www.ncbi.nlm.nih.gov/favicon.ico\" /><meta name=\"ncbi_phid\" content=\"F4FB116881E98C3100000000003E0037\" /><link type=\"text/css\" rel=\"stylesheet\" href=\"//static.pubmed.gov/portal/portal3rc.fcgi/4132802/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4048120/3846471/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4120508/3881636/3579733/4062871/12930/3964959/3855473/4047625/3854974/3854955/4076335/4052581/9685/3549676/3609192/3609193/3609213/3395586/3855312.css\" /><link type=\"text/css\" rel=\"stylesheet\" href=\"//static.pubmed.gov/portal/portal3rc.fcgi/4132802/css/3411343/3882866/3929378.css\" media=\"print\" /></head>\n    <body class=\"article\">\n        <div class=\"grid\">\n            <div class=\"col twelve_col nomargin shadow\">\n                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->\n                <div class=\"sysmessages\">\n                    <noscript>\n\t<p class=\"nojs\">\n\t<strong>Warning:</strong>\n\tThe NCBI web site requires JavaScript to function. \n\t<a href=\"/guide/browsers/#enablejs\" title=\"Learn how to enable JavaScript\" target=\"_blank\">more...</a>\n\t</p>\n\t</noscript>\n                </div>\n                <!--/.sysmessage-->\n                <div class=\"wrap\">\n                    <div class=\"page\">\n                        <div class=\"top\">\n                            <div class=\"universal_header\" id=\"universal_header\"><ul class=\"inline_list jig-ncbimenu ui-ncbimenu resources_list\" id=\"navcontent\"><li class=\"ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt\"><a class=\"ui-ncbimenu-link-first\" href=\"/\" role=\"banner\" title=\"NCBI Home\" id=\"ncbihome\" accesskey=\"1\"><span class=\"offscreen_noflow\">NCBI</span><img src=\"//static.pubmed.gov/portal/portal3rc.fcgi/4132802/img/28977\" class=\"ncbi_logo\" title=\"NCBI\" alt=\"NCBI Logo\" /></a></li><li class=\"offscreen_noflow ui-ncbimenu-item-skip access\"><a href=\"#maincontent\" title=\"Skip to the content\" tabindex=\"0\" accesskey=\"3\">Skip to main\n                        content</a></li><li class=\"offscreen_noflow ui-ncbimenu-item-skip access\"><a href=\"#navcontent\" title=\"Skip to the navigation\" tabindex=\"0\" accesskey=\"4\">Skip to\n                        navigation</a></li><li id=\"resource-menu\" class=\"topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset\"><a class=\"ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown\" href=\"/static/header_footer_ajax/submenu/#resources\">Resources</a></li><li id=\"all-howtos-menu\" class=\"topmenu ui-helper-reset ui-ncbimenu-item-first\"><a class=\"ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown\" href=\"/static/header_footer_ajax/submenu/#howto\">How To</a></li><li class=\"offscreen_noflow ui-ncbimenu-item-skip access\"><a href=\"/guide/browsers/#accesskeys\" title=\"About My NCBI Accesskeys\" tabindex=\"0\" accesskey=\"0\">About NCBI Accesskeys</a></li></ul><div class=\"myncbi\"><span id=\"myncbiusername\" style=\"display:none\"><a href=\"/account/settings/\" id=\"mnu\" title=\"Edit account settings\"></a></span><a accesskey=\"2\" href=\"/myncbi/\" id=\"myncbi\" style=\"display:none\">My NCBI</a><a href=\"/account/\" id=\"sign_in\">Sign in to NCBI</a><a href=\"/account/signout/\" id=\"sign_out\" style=\"display:none\">Sign Out</a></div></div>\n                            <div class=\"header\">\n    <div class=\"res_logo\">\n  <h1 class=\"img_logo\"><a href=\"/pmc/\" class=\"pmc_logo offscreen\">PMC</a></h1>\n  <div class=\"NLMLogo\">\n    <a href=\"https://www.nlm.nih.gov/\" title=\"US National Library of Medicine\">US National Library of Medicine</a>\n    <br />\n    <a href=\"https://www.nih.gov/\" title=\"National Institutes of Health\">National Institutes of Health</a>\n  </div>\n</div>\n    <div class=\"search\"><form method=\"get\" action=\"/pmc/\"><div class=\"search_form\"><label for=\"database\" class=\"offscreen_noflow\">Search database</label><select id=\"database\"><optgroup label=\"Recent\"><option value=\"pmc\" selected=\"selected\" class=\"last\" data-ac_dict=\"pmc-search-autocomplete\">PMC</option></optgroup><optgroup label=\"All\"><option value=\"gquery\">All Databases</option><option value=\"assembly\">Assembly</option><option value=\"bioproject\">BioProject</option><option value=\"biosample\">BioSample</option><option value=\"biosystems\">BioSystems</option><option value=\"books\">Books</option><option value=\"clinvar\">ClinVar</option><option value=\"clone\">Clone</option><option value=\"cdd\">Conserved Domains</option><option value=\"gap\">dbGaP</option><option value=\"dbvar\">dbVar</option><option value=\"nucest\">EST</option><option value=\"gene\">Gene</option><option value=\"genome\">Genome</option><option value=\"gds\">GEO DataSets</option><option value=\"geoprofiles\">GEO Profiles</option><option value=\"nucgss\">GSS</option><option value=\"gtr\">GTR</option><option value=\"homologene\">HomoloGene</option><option value=\"medgen\">MedGen</option><option value=\"mesh\">MeSH</option><option value=\"ncbisearch\">NCBI Web Site</option><option value=\"nlmcatalog\">NLM Catalog</option><option value=\"nuccore\">Nucleotide</option><option value=\"omim\">OMIM</option><option value=\"pmc\" data-ac_dict=\"pmc-search-autocomplete\">PMC</option><option value=\"popset\">PopSet</option><option value=\"probe\">Probe</option><option value=\"protein\">Protein</option><option value=\"proteinclusters\">Protein Clusters</option><option value=\"pcassay\">PubChem BioAssay</option><option value=\"pccompound\">PubChem Compound</option><option value=\"pcsubstance\">PubChem Substance</option><option value=\"pubmed\">PubMed</option><option value=\"pubmedhealth\">PubMed Health</option><option value=\"snp\">SNP</option><option value=\"sparcle\">Sparcle</option><option value=\"sra\">SRA</option><option value=\"structure\">Structure</option><option value=\"taxonomy\">Taxonomy</option><option value=\"toolkit\">ToolKit</option><option value=\"toolkitall\">ToolKitAll</option><option value=\"toolkitbook\">ToolKitBook</option><option value=\"toolkitbookgh\">ToolKitBookgh</option><option value=\"unigene\">UniGene</option></optgroup></select><div class=\"nowrap\"><label for=\"term\" class=\"offscreen_noflow\" accesskey=\"/\">Search term</label><div class=\"nowrap\"><input type=\"text\" name=\"term\" id=\"term\" title=\"Search PMC. Use up and down arrows to choose an item from the autocomplete.\" value=\"\" class=\"jig-ncbiclearbutton jig-ncbiautocomplete\" data-jigconfig=\"dictionary:'pmc-search-autocomplete',disableUrl:'NcbiSearchBarAutoComplCtrl'\" autocomplete=\"off\" data-sbconfig=\"ds:'no',pjs:'no',afs:'yes'\" /></div><button id=\"search\" type=\"submit\" class=\"button_search nowrap\" cmd=\"go\">Search</button></div></div></form><ul class=\"searchlinks inline_list\"><li>\n                        <a href=\"/pmc/advanced/\">Advanced</a>\n                    </li><li>\n                        <a href=\"/pmc/journals/\">Journal list</a>\n                    </li><li class=\"help\">\n                        <a target=\"_blank\" href=\"/books/NBK3825/\">Help</a>\n                    </li></ul></div>\n</div>\n\n                            \n                            \n                        <!--<component id=\"Page\" label=\"headcontent\"/>-->\n                            \n                        </div>\n                        <div class=\"content\">\n                            <!-- site messages -->\n                            <div class=\"container\">\n    <div id=\"maincontent\" class=\"content eight_col col\">\n        <div class=\"navlink-box\">\n            <ul class=\"page-breadcrumbs inline_list small\"><li class=\"journal-list\"><a href=\"/pmc/journals/\" class=\"navlink\">Journal List</a></li><li class=\"article-entrez-filter\"><a href=\"/pmc/?term=%22Blood%22[journal]\" class=\"navlink\">Blood</a></li><li class=\"accid\">PMC1895765</li></ul>\n        </div>\n\n        <!-- Journal banner -->\n        <div class=\"pmc-page-banner whole_rhythm\"><div><img src=\"/corehtml/pmc/pmcgifs/logo-blood.gif\" alt=\"Logo of blood\" usemap=\"#logo-imagemap\" /><map id=\"logo-imagemap\" name=\"logo-imagemap\"><area shape=\"rect\" coords=\"139,56,200,76\" alt=\"Original Article\" title=\"Original Article\" href=\"http://bloodjournal.hematologylibrary.org/cgi/content/full/107/9/3436\" ref=\"reftype=publisher&amp;article-id=1895765&amp;issue-id=141776&amp;journal-id=446&amp;FROM=Article%7CBanner&amp;TO=Publisher%7CArticle%7CFullText&amp;rendering-type=normal\" target=\"pmc_ext\" /><area shape=\"rect\" coords=\"0,0,157,57\" alt=\"Blood Journal\" title=\"Blood Journal\" href=\"http://bloodjournal.hematologylibrary.org/\" ref=\"reftype=publisher&amp;article-id=1895765&amp;issue-id=141776&amp;journal-id=446&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A&amp;rendering-type=normal\" target=\"pmc_ext\" /><area shape=\"rect\" coords=\"200,56,258,76\" alt=\"Current Issue\" title=\"Current Issue\" href=\"http://bloodjournal.hematologylibrary.org/current.dtl\" ref=\"reftype=publisher&amp;article-id=1895765&amp;issue-id=141776&amp;journal-id=446&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A&amp;rendering-type=normal\" target=\"pmc_ext\" /><area shape=\"rect\" coords=\"257,56,311,76\" alt=\"About Blood\" title=\"About Blood\" href=\"http://bloodjournal.hematologylibrary.org/about/index.dtl\" ref=\"reftype=publisher&amp;article-id=1895765&amp;issue-id=141776&amp;journal-id=446&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A&amp;rendering-type=normal\" target=\"pmc_ext\" /><area shape=\"rect\" coords=\"309,56,364,77\" alt=\"Submissions\" title=\"Submissions\" href=\"http://submit.bloodjournal.org/\" ref=\"reftype=publisher&amp;article-id=1895765&amp;issue-id=141776&amp;journal-id=446&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A&amp;rendering-type=normal\" target=\"pmc_ext\" /><area shape=\"rect\" coords=\"363,56,420,78\" alt=\"Subscriptions\" title=\"Subscriptions\" href=\"http://bloodjournal.hematologylibrary.org/subscriptions/index.dtl\" ref=\"reftype=publisher&amp;article-id=1895765&amp;issue-id=141776&amp;journal-id=446&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A&amp;rendering-type=normal\" target=\"pmc_ext\" /><area shape=\"rect\" coords=\"418,56,476,76\" alt=\"Contact Us\" title=\"Contact Us\" href=\"http://bloodjournal.hematologylibrary.org/misc/contact.dtl\" ref=\"reftype=publisher&amp;article-id=1895765&amp;issue-id=141776&amp;journal-id=446&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A&amp;rendering-type=normal\" target=\"pmc_ext\" /><area shape=\"poly\" coords=\"450,2,431,9,425,27,429,43,437,54,459,55,471,52,483,42,486,29,479,11,466,2,449,2\" alt=\"ASH Homepage\" title=\"ASH Homepage\" href=\"http://www.hematology.org\" ref=\"reftype=publisher&amp;article-id=1895765&amp;issue-id=141776&amp;journal-id=446&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A&amp;rendering-type=normal\" target=\"pmc_ext\" /></map></div> </div>\n        \n        <!--component id='MainPortlet' label='search-reference'/-->\n        \n        <!-- Book content -->\n        <div class=\"\">\n            \n        \n            \n            <div class=\"hide-overflow article lit-style content pmc-wm slang-all page-box\"><!--main-content--><div class=\"jig-ncbiinpagenav\" data-jigconfig=\"smoothScroll: false, allHeadingLevels: ['h2'], headingExclude: ':hidden'\"><div class=\"fm-sec half_rhythm no_top_margin\"><div class=\"fm-citation half_rhythm no_top_margin clearfix\"><div class=\"small\"><div class=\"inline_block eight_col va_top\"><div><div><span class=\"cit\"><span id=\"pmcmata\">Blood</span>. 2006 May 1; 107(9): 3436\u20133441. </span></div><div><span class=\"fm-vol-iss-date\">Prepublished online 2006 Mar 7. </span>  <span class=\"doi\">doi:\u00a0 <a href=\"//dx.doi.org/10.1182%2Fblood-2006-02-002394\" target=\"pmc_ext\" ref=\"reftype=other&amp;article-id=1895765&amp;issue-id=141776&amp;journal-id=446&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI&amp;rendering-type=normal\">10.1182/blood-2006-02-002394</a></span></div></div></div><div class=\"inline_block four_col va_top show-overflow align_right\"><div class=\"fm-citation-ids\"><div class=\"fm-citation-pmcid\"><span class=\"fm-citation-ids-label\">PMCID: </span><span>PMC1895765</span></div></div></div></div></div><h1 class=\"content-title\">Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions</h1><div class=\"half_rhythm\"><div class=\"contrib-group fm-author\"><a href=\"/pubmed/?term=Neufeld%20EJ%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=16627763\">Ellis J. Neufeld</a></div></div><div class=\"fm-panel small half_rhythm\"><div class=\"fm-authors-info fm-panel hide half_rhythm\" id=\"id484460_ai\" style=\"display:none\"><div class=\"fm-affl\" lang=\"en\">From the Division of Hematology/Oncology, Children's Hospital, Boston, MA; and the Dana Farber Cancer Institute and Harvard Medical School, Boston, MA.</div><div id=\"__fnid483926\"><strong>Reprints:</strong> Ellis J. Neufeld, Division of Hematology, Children's Hospital, Karp 08210, 300 Longwood Ave, Boston, MA 02115; e-mail: <a href=\"mailto:dev@null\" data-email=\"ude.dravrah.snerdlihc@dlefuen.sille\" class=\"oemail\">ude.dravrah.snerdlihc@dlefuen.sille</a>. </div></div><div class=\"togglers\"><a href=\"#\" class=\"pmctoggle\" rid=\"id484460_ai\">Author information <span>\u25ba</span></a> <a href=\"#\" class=\"pmctoggle\" rid=\"id484460_an\">Article notes <span>\u25ba</span></a> <a href=\"#\" class=\"pmctoggle\" rid=\"id484460_cpl\">Copyright and License information <span>\u25ba</span></a></div><div class=\"fm-article-notes fm-panel hide half_rhythm\" id=\"id484460_an\" style=\"display:none\"><div class=\"fm-pubdate half_rhythm\">Received 2006 Feb 28; Accepted 2006 Mar 3.</div></div><div class=\"fm-cpl-info fm-panel hide half_rhythm\" id=\"id484460_cpl\" style=\"display:none\"><div class=\"fm-copyright half_rhythm\"><a href=\"/pmc/about/copyright/\">Copyright</a>  &#x000a9; 2006, The American Society of Hematology</div></div></div><div id=\"pmclinksbox\" class=\"links-box fm-panel whole_rhythm\"><div class=\"small\"><div>This article has been <a href=\"/pmc/articles/PMC1895765/citedby/\">cited by</a> other articles in PMC.</div></div></div></div><div class=\"sec\"></div><div id=\"__abstractid447364\" lang=\"en\" class=\"tsec sec\"><h2 class=\"head no_bottom_margin\" id=\"__abstractid447364title\">Abstract</h2><!--article-meta--><div><p id=\"__p2\" class=\"p p-first-last\">For nearly 30 years, patients with transfusional iron overload have depended on nightly deferoxamine infusions for iron chelation. Despite dramatic gains in life expectancy in the deferoxamine era for patients with transfusion-dependent anemias, the leading cause of death for young adults with thalassemia major and related disorders has been cardiac disease from myocardial iron deposition. Strategies to reduce cardiac disease by improving chelation regimens have been of the highest priority. These strategies have included development of novel oral iron chelators to improve compliance, improved assessment of cardiac iron status, and careful epidemiologic assessment of European outcomes with deferiprone, an oral alternative chelator available for about a decade. Each of these strategies is now bearing fruit. The novel oral chelator deferasirox was recently approved by the Food and Drug Administration (FDA); a randomized clinical trial demonstrates that deferasirox at 20 to 30 mg/kg/d can maintain or improve hepatic iron in thalassemia as well as deferoxamine. A randomized trial based on cardiac T2* magnetic resonance imaging (MRI) suggests that deferiprone can unload myocardial iron faster than deferoxamine. Retrospective epidemiologic data suggest dramatic reductions in cardiac events and mortality in Italian subjects exposed to deferiprone compared with deferoxamine. These developments herald a new era for iron chelation, but many unanswered questions remain.</p></div></div><div id=\"__sec1\" class=\"tsec sec\"><h2 class=\"head no_bottom_margin\" id=\"__sec1title\">Introduction</h2><p id=\"__p6\" class=\"p p-first-last\">In this issue of <em>Blood,</em> there are reports of 2 randomized clinical trials and a large retrospective epidemiology study that represent crucial advances in the field of oral agents to treat transfusional iron overload in thalassemia.<sup><a href=\"#ref1\" rid=\"ref1\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_131133007\">1</a></sup><sup>-</sup><sup><a href=\"#ref3\" rid=\"ref3\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_131132982\">3</a></sup> Here I will summarize the results of these studies, point out some of their strengths and weaknesses, and propose one hematologist's view of where this work leaves the field.</p></div><div id=\"__sec2\" class=\"tsec sec\"><h2 class=\"head no_bottom_margin\" id=\"__sec2title\">Three iron chelators: parenteral versus oral</h2><div id=\"__sec3\" class=\"sec sec-first\"><h3>Deferoxamine</h3><p id=\"__p7\" class=\"p p-first-last\">Deferoxamine (DFO; Desferal and generic) has been the standard iron chelator since the 1970s. DFO is both safe and effective for transfusional hemosiderosis. A hexadentate chelator, it binds iron tightly, and the iron-DFO complex is excreted in both urine and stool. DFO is administered as long parenteral infusions because the plasma half-life is short (minutes) and it is not active orally. Thus, it is given as an overnight subcutaneous infusion 5 to 7 nights/wk. The DFO-iron chelate is charged and does not readily enter and leave cells.<sup><a href=\"#ref4\" rid=\"ref4\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_131132993\">4</a></sup> Parenteral administration and the daily nuisance of an infusion pump hinder optimal compliance. Nevertheless, in the DFO era, over the past generation, dramatic strides in survival of thalassemia patients have occurred.<sup><a href=\"#ref5\" rid=\"ref5\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_131133015\">5</a></sup></p></div><div id=\"__sec4\" class=\"sec\"><h3>Deferiprone</h3><p id=\"__p8\" class=\"p p-first-last\">Deferiprone (Ferriprox and others) is an orally active hydroxypyridineone first used in humans in 1987. Deferiprone is a bidentate chelator (3 molecules surround one iron ion). An advantage of this compound is that the iron(III) chelate of deferiprone carries no net charge and therefore can penetrate membranes easily, allowing removal of potentially toxic iron from tissues.<sup><a href=\"#ref6\" rid=\"ref6\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_131132985\">6</a></sup> Many <em>Blood</em> readers are aware of a controversy over the safety of deferiprone that arose in the late 1990s because of an observation of hepatic fibrosis during a clinical trial.<sup><a href=\"#ref7\" rid=\"ref7\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_131133005\">7</a></sup> However, in subsequent studies this problem has not been a significant toxicity issue for deferiprone.<sup><a href=\"#ref8\" rid=\"ref8\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_131132997\">8</a></sup> The history of deferiprone and this safety debate were well summarized in a 2003 <em>Blood</em> &#x0201c;Perspective.&#x0201d;<sup><a href=\"#ref9\" rid=\"ref9\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_131133006\">9</a></sup> Deferiprone often causes gastrointestinal symptoms. Idiosyncratic side effects that are potentially severe include erosive arthritis (common in patients in South Asian countries, from 5% to &#x0003e; 20%) and neutropenia (up to 5% of patients), including severe agranulocytosis (up to 0.5% of patients); close monitoring is required. Typical dosage for deferiprone is 75 mg/kg/d in 3 divided doses, up to 100 mg/kg daily.<sup><a href=\"#ref3\" rid=\"ref3\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_131133001\">3</a></sup><sup>,</sup><sup><a href=\"#ref10\" rid=\"ref10\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_131132998\">10</a></sup></p></div><div id=\"__sec5\" class=\"sec sec-last\"><h3>Deferasirox</h3><p id=\"__p9\" class=\"p p-first\">Deferasirox (ICL670, Exjade) belongs to a new class of oral tridentate chelator, N-substituted bis-hydroxyphenyltriazoles. Deferasirox, the result of a concerted discovery program, underwent extensive safety testing and clinical trials including preclinical studies,<sup><a href=\"#ref11\" rid=\"ref11\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_131132999\">11</a></sup> initial phase 1 and iron balance studies,<sup><a href=\"#ref12\" rid=\"ref12\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_131132980\">12</a></sup> phase 2 efficacy studies in adult<sup><a href=\"#ref13\" rid=\"ref13\" class=\" bibr popnode\">13</a></sup> and pediatric<sup><a href=\"#ref14\" rid=\"ref14\" class=\" bibr popnode\">14</a></sup> thalassemia patients, patients with a variety of anemias or unable/noncompliant with DFO,<sup><a href=\"#ref15\" rid=\"ref15\" class=\" bibr popnode\">15</a></sup> and the phase 3 clinical trial discussed here.<sup><a href=\"#ref1\" rid=\"ref1\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_131132987\">1</a></sup> With a plasma half-life of 8 to 16 hours, once-daily dosing permits circulating drug at all times to scavenge non&#x02013;transferrin-bound &#x0201c;labile plasma iron,&#x0201d;<sup><a href=\"#ref16\" rid=\"ref16\" class=\" bibr popnode\">16</a></sup> the chemical species responsible for tissue damage in iron-overloaded subjects, by means of toxic oxygen intermediaries.<sup><a href=\"#ref17\" rid=\"ref17\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_131132991\">17</a></sup> Deferasirox-iron complexes are excreted in the stool.</p><p id=\"__p10\" class=\"p p-last\">The 3 compounds are compared in <a href=\"/pmc/articles/PMC1895765/table/tbl1/\" target=\"true\" class=\"fig-table-link table figpopup\" rid-figpopup=\"tbl1\" rid-ob=\"ob-tbl1\" co-legend-rid=\"\"><span>Table 1</span></a> to properties of an ideal chelator. One &#x0201c;theoretical&#x0201d; advantage with real clinical import is access of chelators to intracellular iron, particularly in cardiac myocytes. In cultured heart muscle, deferasirox and deferiprone have rapid access to intracellular iron pools, whereas DFO does not.<sup><a href=\"#ref18\" rid=\"ref18\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_131133011\">18</a></sup> Nevertheless, high-dose continuous DFO, administered via central catheter, can dramatically reverse cardiac toxicity of iron overload.<sup><a href=\"#ref4\" rid=\"ref4\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_131132994\">4</a></sup> High-dose continuous DFO has been the &#x0201c;standard&#x0201d; initial therapy for cardiac iron overload.</p><!--table ft1--><!--table-wrap mode=article t1--><div class=\"table-wrap iconblock ten_col whole_rhythm clearfix\" id=\"tbl1\"><a href=\"/pmc/articles/PMC1895765/table/tbl1/\" target=\"table\" rid-ob=\"ob-tbl1\" rid-figpopup=\"tbl1\" class=\"table img_link icnblk_img figpopup\"><img alt=\"Table 1.\" title=\"Table 1.\" class=\"small-thumb\" src=\"/pmc/articles/PMC1895765/table/tbl1/?report=thumb\" src-large=\"/pmc/articles/PMC1895765/table/tbl1/?report=previmg\" /></a><div class=\"icnblk_cntnt\"><div><a class=\"figpopup\" href=\"/pmc/articles/PMC1895765/table/tbl1/\" target=\"table\" rid-figpopup=\"tbl1\" rid-ob=\"ob-tbl1\">Table 1.</a></div><!--caption a4--><div><span><strong>Comparison of available iron chelators to an ideal chelation drug</strong></span></div></div></div></div></div><div id=\"__sec6\" class=\"tsec sec\"><h2 class=\"head no_bottom_margin\" id=\"__sec6title\">Clinical assessments of chelator efficacy and novel noninvasive measures of iron overload</h2><p id=\"__p11\" class=\"p p-first-last\">Trials to test chelator effectiveness necessarily require a choice of a primary outcome measure. Potential &#x0201c;hard&#x0201d; end points or surrogates are summarized in <a href=\"/pmc/articles/PMC1895765/table/tbl2/\" target=\"true\" class=\"fig-table-link table figpopup\" rid-figpopup=\"tbl2\" rid-ob=\"ob-tbl2\" co-legend-rid=\"\"><span>Table 2</span></a>. Different outcomes were chosen for the 3 studies discussed here. (1) Hepatic iron content (HIC) by liver biopsy was used for the deferasirox-versus-DFO trial.<sup><a href=\"#ref1\" rid=\"ref1\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_131132996\">1</a></sup> Liver biopsy has been the &#x0201c;gold standard&#x0201d; for iron balance studies, but the technique is invasive, expensive, and subject to variability within and between research subjects. (2) The epidemiologic study of deferiprone examines onset of symptomatic cardiac disease as the primary outcome measure.<sup><a href=\"#ref2\" rid=\"ref2\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_131132978\">2</a></sup> This is a compelling end point because iron-related cardiac disease is a major clinical problem. (3) For their comparative trial of DFO and deferiprone, Pennell and colleagues<sup><a href=\"#ref3\" rid=\"ref3\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_131132977\">3</a></sup> used the cardiac magnetic resonance imaging (MRI) parameter T2* (pronounced &#x0201c;T-2-star&#x0201d;). Iron concentration in tissues (in this case, the myocardium of the cardiac septum) is inversely related to T2*. Low T2* values (&#x0003c; 8 ms compared with normal [&#x0003e; 20 ms]) are related to risk of heart failure and death in iron-overloaded thalassemia patients.<sup><a href=\"#ref20\" rid=\"ref20\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_131132983\">20</a></sup> T2* reports initially raised concerns about whether it is a good surrogate for cardiac iron concentration<sup><a href=\"#ref25\" rid=\"ref25\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_131132975\">25</a></sup> for technical reasons as well as the paradox that liver iron correlated poorly with cardiac T2*. These points have largely been settled. In an iron-overload gerbil model, T2* is indeed inversely related to myocardial iron measured directly.<sup><a href=\"#ref26\" rid=\"ref26\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_196427584\">26</a></sup> The poor correlation of T2* with hepatic iron is now understood on a kinetic basis. The liver can be readily unloaded by aggressive chelation much more rapidly than can the heart, giving rise to patients with low T2* values (heart still iron loaded) while the liver has been unloaded to values previously thought of as &#x0201c;safe.&#x0201d;<sup><a href=\"#ref27\" rid=\"ref27\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_131133013\">27</a></sup></p><!--table ft1--><!--table-wrap mode=article t1--><div class=\"table-wrap iconblock ten_col whole_rhythm clearfix\" id=\"tbl2\"><a href=\"/pmc/articles/PMC1895765/table/tbl2/\" target=\"table\" rid-ob=\"ob-tbl2\" rid-figpopup=\"tbl2\" class=\"table img_link icnblk_img figpopup\"><img alt=\"Table 2.\" title=\"Table 2.\" class=\"small-thumb\" src=\"/pmc/articles/PMC1895765/table/tbl2/?report=thumb\" src-large=\"/pmc/articles/PMC1895765/table/tbl2/?report=previmg\" /></a><div class=\"icnblk_cntnt\"><div><a class=\"figpopup\" href=\"/pmc/articles/PMC1895765/table/tbl2/\" target=\"table\" rid-figpopup=\"tbl2\" rid-ob=\"ob-tbl2\">Table 2.</a></div><!--caption a4--><div><span><strong>Example of outcome measures for chelator trials and their application for clinical practice now and in the future</strong></span></div></div></div></div><div id=\"__sec7\" class=\"tsec sec\"><h2 class=\"head no_bottom_margin\" id=\"__sec7title\">Randomized clinical trial of deferiprone versus deferoxamine</h2><p id=\"__p12\" class=\"p p-first-last\">Pennell et al<sup><a href=\"#ref3\" rid=\"ref3\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_131132990\">3</a></sup> compared oral deferiprone to subcutaneous DFO in 61 thalassemia major patients without symptomatic heart failure. The entry criteria required T2* to be abnormal (&#x0003c; 20 ms) but not &#x0201c;severe&#x0201d; (&#x0003c; 8 ms) and left ventricular ejection fraction (LVEF) to be greater than 56%. Technical details of the single-breath-hold T2* method were previously published.<sup><a href=\"#ref28\" rid=\"ref28\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_131132989\">28</a></sup> Superconducting quantum interference device (SQUID; <a href=\"/pmc/articles/PMC1895765/table/tbl2/\" target=\"true\" class=\"fig-table-link table figpopup\" rid-figpopup=\"tbl2\" rid-ob=\"ob-tbl2\" co-legend-rid=\"\"><span>Table 2</span></a>) was used to measure HIC at baseline and 12 months. Compliance was closely monitored. The primary outcome measure was change in myocardial T2* at 6 and 12 months. The rate of rise in T2* was significantly higher to deferiprone (mean dose 92 mg/kg/d) than to DFO (mean dose of 43 mg/kg, 5.7 d/wk). In addition, there was a greater increase in LVEF in the deferiprone group compared with the deferoxamine group, all within the &#x0201c;normal&#x0201d; range. Mean HIC fell slightly in each group. Gastrointestinal symptoms and joint pain were common side effects. This prospective trial validates the prior retrospective series of Anderson et al<sup><a href=\"#ref29\" rid=\"ref29\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_131133009\">29</a></sup> that had been controversial.<sup><a href=\"#ref25\" rid=\"ref25\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_131133014\">25</a></sup> A potential weakness of the trial is the use of the surrogate T2* as primary outcome, because the clinical significance of a few more milliseconds within the mildly abnormal range is unknown if taken alone. However, taken together with in vitro data and with the epidemiologic data of Borgna-Pignatti et al,<sup><a href=\"#ref2\" rid=\"ref2\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_131132988\">2</a></sup> this trial provides important further evidence that, despite the concerns about deferiprone chelation efficiency based on 3:1 stoichiometry, deferiprone is probably better in vivo at improving myocardial iron than DFO (at the doses used).</p></div><div id=\"__sec8\" class=\"tsec sec\"><h2 class=\"head no_bottom_margin\" id=\"__sec8title\">Efficacy of a new oral iron chelator</h2><p id=\"__p13\" class=\"p p-first\">Phase 3 trial results for deferasirox in a randomized controlled comparison trial with DFO are reported by Cappellini and colleagues.<sup><a href=\"#ref1\" rid=\"ref1\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_131133008\">1</a></sup> The trial involved nearly 600 patients (half were 16 years of age or younger) with transfusion-dependent &#x003b2;-thalassemia. The study was designed as a noninferiority trial, measuring hepatic iron by biopsy at baseline and after one year of therapy. Success was defined as either maintenance or improvement in HIC (depending on the baseline levels). Based on the study results, the United States Food and Drug Administration (FDA) approved the drug for transfusional iron overload for patients older than 2 years of age in November 2005. The drug is still under regulatory review in Europe.</p><p id=\"__p14\" class=\"p p-last\">This report deserves careful scrutiny from hematologists who care for patients with thalassemia and other disorders of transfusional iron overload. The dose choices for DFO and for deferasirox were based solely on baseline HIC at study entry. The decision to use this baseline value and the choice of what are now known to be relatively low deferasirox doses caused the study to fail to meet its overall primary end point (ie, at low doses of deferasirox, 5-10 mg/kg/d, increased HIC was observed). However, at doses of 20 to 30 mg/kg/d, the doses for HIC greater than 7 mg/g dry weight, noninferiority of deferasirox compared with DFO was established, with 60% versus 59% achieving a successful outcome, respectively. Assessed by ferritin concentration, 20 mg/kg/d deferasirox was sufficient to maintain mean ferritin levels over 52 weeks, whereas 30 mg/kg yielded a reduction in ferritin level. In retrospect, several design decisions contributed to the mixed outcome of &#x0201c;failure&#x0201d; at low doses and success at higher doses. For example, results from an earlier phase 2 trial of deferasirox in children,<sup><a href=\"#ref14\" rid=\"ref14\" class=\" bibr popnode\">14</a></sup> which also used low doses that proved ineffective, were not available in time to guide the phase 3 trial. As well, additional factors proved important in deferasirox efficacy. For example, transfused iron burden was shown to be a strong predictor of the iron response at a year.<sup><a href=\"#ref30\" rid=\"ref30\" class=\" bibr popnode\">30</a></sup><sup>,</sup><sup><a href=\"#ref31\" rid=\"ref31\" class=\" bibr popnode\">31</a></sup> Likelihood of failing to achieve iron balance was much higher for patients receiving more than 0.5 mg/kg/d iron.<sup><a href=\"#ref31\" rid=\"ref31\" class=\" bibr popnode\">31</a></sup> Adverse drug reactions in deferasirox trials have included modest rise in creatinine level, rarely clinically significant. Increased transaminases were observed occasionally. Common side effects of deferasirox include transient gastrointestinal symptoms in 15% and rash in 11%.</p></div><div id=\"__sec9\" class=\"tsec sec\"><h2 class=\"head no_bottom_margin\" id=\"__sec9title\">An epidemiologic assessment of onset of cardiac disease in DFO- or deferiprone-treated patients with thalassemia</h2><p id=\"__p15\" class=\"p p-first-last\">Borgna-Pignatti and colleagues<sup><a href=\"#ref2\" rid=\"ref2\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_131132981\">2</a></sup> present an interesting retrospective cohort study of cardiac events in Italian thalassemia patients who switched from DFO to deferiprone. The study included more than 500 patients with thalassemia major at 7 large Italian centers who were alive in 1995 and who had neither prior heart disease nor subsequent marrow transplantation. Deferiprone was given to 157 subjects during some period in the subsequent 9 years, whereas 359 received only DFO. Many of the deferiprone patients were initially part of clinical trials, before the drug became available on a compassionate-use basis in 1997 and commercially in 2000. In a time-to-event analysis, the authors noted 52 cardiac events, including 10 deaths, in patients while on DFO and 0 events while on deferiprone. The result is dramatic and unexpected, whether one believes that deferiprone would have been given mostly to DFO-intolerant patients or not. Although potential bias could easily arise in a retrospective study of unmatched groups, the authors have examined possible biases in a comprehensive fashion, controlling for as many as possible, and explaining the rest with admirable clarity and near-perfect patient ascertainment. This stunning finding, coupled with similar but less rigorous data from other sites, is hard to ignore. The results confirmed a smaller retrospective analysis of Piga et al.<sup><a href=\"#ref32\" rid=\"ref32\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_131133004\">32</a></sup></p></div><div id=\"__sec10\" class=\"tsec sec\"><h2 class=\"head no_bottom_margin\" id=\"__sec10title\">Cost comparison of DFO and deferasirox</h2><p id=\"__p16\" class=\"p p-first-last\">Perfect and unbiased cost comparisons among commercial versions of all 3 drugs are not yet possible for any single country, and national price differences abound. Although a rough first-order approximation of price ranking might be deferiprone &#x0003c; deferoxamine &#x0003c; deferasirox, this may not be true in every country (<a href=\"/pmc/articles/PMC1895765/table/tbl3/\" target=\"true\" class=\"fig-table-link table figpopup\" rid-figpopup=\"tbl3\" rid-ob=\"ob-tbl3\" co-legend-rid=\"\"><span>Table 3</span></a> provides some comparisons of available costs). Nondrug obligatory costs are important as well: deferiprone therapy requires weekly complete blood count (CBC)/differential count; DFO requires ancillary supplies for infusion. Deferasirox will cost more than twice as much as DFO in the United States. At least until deferasirox, chelators heretofore have not been the major cost of caring for American thalassemia patients; this dubious honor goes to the transfusions themselves.<sup><a href=\"#ref35\" rid=\"ref35\" class=\" bibr popnode\">35</a></sup> But the cost of deferasirox will be a significant new burden even in developed nations with strong health insurance programs, and it will be prohibitive in the developing world, without substantial discounts. An initial attempt at cost-effectiveness analysis was presented in abstract form at the American Society of Hematology 47th Annual Meeting in 2005, wherein the extra cost of the medication was weighed (favorably) against the cost of illness and death from noncompliance and iron overload for DFO.<sup><a href=\"#ref36\" rid=\"ref36\" class=\" bibr popnode\">36</a></sup> This analysis was sponsored by the manufacturer.</p><!--table ft1--><!--table-wrap mode=article t1--><div class=\"table-wrap iconblock ten_col whole_rhythm clearfix\" id=\"tbl3\"><a href=\"/pmc/articles/PMC1895765/table/tbl3/\" target=\"table\" rid-ob=\"ob-tbl3\" rid-figpopup=\"tbl3\" class=\"table img_link icnblk_img figpopup\"><img alt=\"Table 3.\" title=\"Table 3.\" class=\"small-thumb\" src=\"/pmc/articles/PMC1895765/table/tbl3/?report=thumb\" src-large=\"/pmc/articles/PMC1895765/table/tbl3/?report=previmg\" /></a><div class=\"icnblk_cntnt\"><div><a class=\"figpopup\" href=\"/pmc/articles/PMC1895765/table/tbl3/\" target=\"table\" rid-figpopup=\"tbl3\" rid-ob=\"ob-tbl3\">Table 3.</a></div><!--caption a4--><div><span><strong>Relative estimated cost of deferaprone, deferoxamine, and deferasirox</strong><sup>*</sup></span></div></div></div></div><div id=\"__sec11\" class=\"tsec sec\"><h2 class=\"head no_bottom_margin\" id=\"__sec11title\">Additional recent studies of deferasirox</h2><p id=\"__p17\" class=\"p p-first-last\">More than 20 deferasirox abstracts were presented at the 2005 American Society of Hematology Annual Meeting. These included clear evidence from both phase 2 and phase 3 clinical trials that transfusional iron loading (expressed as mg/kg/d of transfused iron) had a dramatic effect on the ability of deferasirox doses to maintain or reduce hepatic iron<sup><a href=\"#ref30\" rid=\"ref30\" class=\" bibr popnode\">30</a></sup><sup>,</sup><sup><a href=\"#ref31\" rid=\"ref31\" class=\" bibr popnode\">31</a></sup> and presentation of the randomized trial of deferasirox versus DFO in sickle cell disease.<sup><a href=\"#ref37\" rid=\"ref37\" class=\" bibr popnode\">37</a></sup> Porter et al<sup><a href=\"#ref38\" rid=\"ref38\" class=\" bibr popnode\">38</a></sup> demonstrated improved cardiac T2* with deferasirox in patients from their site in the phase 2 and 3 trials. Molar efficiency of DFO and deferasirox was compared by examining net iron balance as a function of input transfusional iron and chelator dose.<sup><a href=\"#ref39\" rid=\"ref39\" class=\" bibr popnode\">39</a></sup> These results have important implications to consider along with the phase 3 trial<sup><a href=\"#ref1\" rid=\"ref1\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_131133002\">1</a></sup>: chelator efficiency and clinical effectiveness in vivo are not a function of chelate stoichiometry alone. Iron removal also depends on achievable plasma concentration, host factors, degree of loading, and rate of accessibility of stored iron to chelator.</p></div><div id=\"__sec12\" class=\"tsec sec\"><h2 class=\"head no_bottom_margin\" id=\"__sec12title\">Clinical utility of the data from the 3 new studies</h2><div id=\"__sec13\" class=\"sec sec-first\"><h3>How can data from these 3 studies best be applied to current practice?</h3><p id=\"__p18\" class=\"p p-first\">For treaters and patients, a prudent path would be first to take to heart the main messages of each of the 3 studies. I believe these are the take-home messages. (1) Cappellini et al<sup><a href=\"#ref1\" rid=\"ref1\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_131133012\">1</a></sup> show that at 20 to 30 mg/kg/d, deferasirox can keep most <em>but not all</em> patients in even or negative iron balance in rough equivalence with moderate doses of DFO. (2) Pennell et al<sup><a href=\"#ref3\" rid=\"ref3\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_131133010\">3</a></sup> prove that deferiprone was able to improve not only T2* in asymptomatic patients, but these investigators also provided circumstantial evidence that their patients with &#x0201c;normal&#x0201d; LVEF had subclinical disease, based on improvements in LVEF with chelators. Pennell and colleagues have also initiated a randomized, prospective trial of DFO plus placebo versus DFO plus deferiprone in borderline T2* status; results should soon be published. (3) Borgna-Pignatti et al<sup><a href=\"#ref2\" rid=\"ref2\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_131132992\">2</a></sup> provide the strongest evidence to date that deferiprone should be considered cardioprotective in comparison with DFO, albeit in a retrospective setting without formal matching. But these 3 studies have not yet addressed some crucial questions.</p><p id=\"__p19\"><em><strong>What is the optimum deferasirox dose for patients with high iron intake?</strong></em> Some patients with high transfusion burdens will probably have rising ferritin levels and HICs if treated with the approved doses of 20 to 30 mg/kg/d.</p><p id=\"__p20\">If so, alternative strategies will be obligatory. These might include higher daily doses (which may cause more diarrhea<sup><a href=\"#ref12\" rid=\"ref12\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_131132995\">12</a></sup>), twice-daily dosing, or possible combination regimens with DFO. The latter option would offer lower average price than deferasirox alone (and ideally better net iron chelation) but would lose the advantages of an oral drug. A combination of the 2 oral drugs, deferasirox and deferiprone, requires detailed study before it can be safely recommended.</p><p id=\"__p21\"><em><strong>What is the proper role for deferiprone?</strong></em> Based on side-effect profile alone, in my opinion, deferiprone is likely to remain a &#x0201c;second-line&#x0201d; drug to deferasirox and DFO.</p><p id=\"__p22\">This is not to say that deferiprone will not have a crucial role. In particular, deferiprone plus DFO in some combination appears to be the emerging &#x0201c;treatment of choice&#x0201d; for significant cardiac dysfunction from iron overload, as in vivo<sup><a href=\"#ref40\" rid=\"ref40\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_131132984\">40</a></sup> and in vitro<sup><a href=\"#ref41\" rid=\"ref41\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_131132976\">41</a></sup> evidence support the biochemical rationale.<sup><a href=\"#ref42\" rid=\"ref42\" class=\" bibr popnode\">42</a></sup> Deferiprone is currently available only on a compassionate-use basis in the United States. If deferasirox is successfully used where patients used to be noncompliant with DFO, its main success will be to prevent the need for such rescue therapy altogether.</p><p id=\"__p23\"><em><strong>What shall we tell our patients?</strong></em> In our thalassemia center, we are presenting the approval of deferasirox as a major advance and treatment option.</p><p id=\"__p24\" class=\"p p-last\">After politely receiving this information, however, many DFO users with good compliance and HICs in safe ranges are choosing not to switch until more data become available, because they are doing fine with their pumps and long-term deferasirox data are not yet available. We have not recommended deferasirox to patients with overt myocardial dysfunction because no published data support this use. We now adamantly suggest deferasirox to DFO-noncompliant patients without symptomatic heart disease.</p></div><div id=\"__sec14\" class=\"sec sec-last\"><h3>Further research is crucial</h3><p id=\"__p25\" class=\"p p-first\">Our center is participating in a National Institutes of Health (NIH)&#x02013;sponsored randomized trial comparing intensive DFO plus deferiprone to DFO plus placebo for patients with low LVEF or symptomatic heart disease, and we tell such patients that continuous-infusion DFO is standard care but that addition of deferiprone on study (or for nonstudy participants as compassionate use) may be advantageous. Additional carefully designed studies are required to answer pressing questions about many drug combinations and treatment scenarios. Examples include both small-scale trials (eg, pilot pharmacodynamic studies of the 3 drugs in various combinations) and large-scale efforts (eg, initiation of a randomized, prospective phase 3 trial comparing deferasirox and deferaprone to assess relative safety, efficacy, and cardioprotection).</p><p id=\"__p26\" class=\"p p-last\">We look forward to a future where complications due to iron overload are rare, and our patients certainly look forward to life without &#x0201c;the pump.&#x0201d;</p></div></div><div id=\"__notesid497742\" class=\"tsec sec\"><h2 class=\"head no_bottom_margin\" id=\"__notesid497742title\">Notes</h2><div class=\"fn-group\"><p class=\"fn sec\" id=\"__fnid1151890\">Prepublished online as <em>Blood</em> First Edition Paper, March 7, 2006; DOI 10.1182/blood-2006-02-002394.</p><p class=\"fn sec\" id=\"__fnid452118\">Supported in part by the National Heart, Lung, and Blood Institute (NHLBI) Thalassemia Clinical Research Network grant U01-HL065260.</p><p class=\"fn sec\" id=\"__fnid493871\">Supported by research funding from Novartis for deferasirox clinical trials and serves, unpaid, on the Study Monitoring Committee for a manufacturer-sponsored clinical study of deferasirox.</p></div></div><div id=\"__ref-listid1186175\" class=\"tsec sec\"><h2 class=\"head no_bottom_margin\" id=\"__ref-listid1186175title\">References</h2><div class=\"ref-list-sec sec\" id=\"reference-list\"><div class=\"ref-cit-blk half_rhythm\" id=\"ref1\">1. <span class=\"citation\">Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with {beta}-thalassemia. <span class=\"ref-journal\">Blood</span>. 2005;<span class=\"ref-vol\">107</span>: 3455-3462.  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/16352812\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=1895765&amp;issue-id=141776&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"ref2\">2. <span class=\"citation\">Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. <span class=\"ref-journal\">Blood</span>. 2005;<span class=\"ref-vol\">107</span>: 3733-3737.  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/16373663\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=1895765&amp;issue-id=141776&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"ref3\">3. <span class=\"citation\">Pennell DJ, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. <span class=\"ref-journal\">Blood</span>. 2005;<span class=\"ref-vol\">107</span>: 3738-3744.  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/16352815\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=1895765&amp;issue-id=141776&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"ref4\">4. <span class=\"citation\">Davis BA, Porter JB. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia. <span class=\"ref-journal\">Blood</span>. 2000;<span class=\"ref-vol\">95</span>: 1229-1236.  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/10666195\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=1895765&amp;issue-id=141776&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"ref5\">5. <span class=\"citation\">Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. <span class=\"ref-journal\">Haematologica</span>. 2004;<span class=\"ref-vol\">89</span>: 1187-1193.  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/15477202\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=1895765&amp;issue-id=141776&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"ref6\">6. <span class=\"citation\">Hider RC, Zhou T. The design of orally active iron chelators. <span class=\"ref-journal\">Ann N Y Acad Sci</span>. 2005;<span class=\"ref-vol\">1054</span>: 141-154.  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/16339660\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=1895765&amp;issue-id=141776&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"ref7\">7. <span class=\"citation\">Olivieri NF, Brittenham GM, McLaren CE, et al. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. <span class=\"ref-journal\">N Engl J Med</span>. 1998;<span class=\"ref-vol\">339</span>: 417-423.  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/9700174\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=1895765&amp;issue-id=141776&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"ref8\">8. <span class=\"citation\">Cohen AR, Galanello R, Piga A, De Sanctis V, Tricta F. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. <span class=\"ref-journal\">Blood</span>. 2003;<span class=\"ref-vol\">102</span>: 1583-1587.  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/12763939\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=1895765&amp;issue-id=141776&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"ref9\">9. <span class=\"citation\">Hoffbrand AV, Cohen A, Hershko C. Role of deferiprone in chelation therapy for transfusional iron overload. <span class=\"ref-journal\">Blood</span>. 2003;<span class=\"ref-vol\">102</span>: 17-24.  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/12637334\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=1895765&amp;issue-id=141776&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"ref10\">10. <span class=\"citation\">Taher A, Sheikh-Taha M, Sharara A, et al. Safety and effectiveness of 100 mg/kg/day deferiprone in patients with thalassemia major: a two-year study. <span class=\"ref-journal\">Acta Haematol</span>. 2005;<span class=\"ref-vol\">114</span>: 146-149.  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/16227677\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=1895765&amp;issue-id=141776&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"ref11\">11. <span class=\"citation\">Hershko C, Konijn AM, Nick HP, Breuer W, Cabantchik ZI, Link G. ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture. <span class=\"ref-journal\">Blood</span>. 2001;<span class=\"ref-vol\">97</span>: 1115-1122.  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/11159545\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=1895765&amp;issue-id=141776&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"ref12\">12. <span class=\"citation\">Nisbet-Brown E, Olivieri NF, Giardina PJ, et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. <span class=\"ref-journal\">Lancet</span>. 2003;<span class=\"ref-vol\">361</span>: 1597-1602.  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/12747879\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=1895765&amp;issue-id=141776&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"ref13\">13. <span class=\"citation\">Piga A, Galanello R, Cappellini MD, et al. Phase II study of ICL670, an oral chelator, in adult thalassaemia patients with transfusional iron overload: efficacy, safety, pharmaco kinetics (PK) and pharmacodynamics (PD) after 18 months of therapy [abstract]. <span class=\"ref-journal\">Blood</span>. 2003;<span class=\"ref-vol\">102</span>: 121a. Abstract 412.</span></div><div class=\"ref-cit-blk half_rhythm\" id=\"ref14\">14. <span class=\"citation\">Piga A, Galanello R, Foschini ML, et al. Once-daily treatment with the oral iron chelator ICL670 (Exjade (R)): results of a phase II study in pediatric patients with beta-thalassemia major [abstract]. <span class=\"ref-journal\">Blood</span>. 2004;<span class=\"ref-vol\">104</span>: 983a. Abstract 3614.</span></div><div class=\"ref-cit-blk half_rhythm\" id=\"ref15\">15. <span class=\"citation\">Porter J, Vichinsky E, Rose C, et al. A phase II study with ICL670 (Exjade((R))), a once-daily oral iron chelator, in patients with various transfusion-dependent anemias and iron overload [abstract]. <span class=\"ref-journal\">Blood</span>. 2004;<span class=\"ref-vol\">104</span>: 872a. Abstract 3193.</span></div><div class=\"ref-cit-blk half_rhythm\" id=\"ref16\">16. <span class=\"citation\">Daar S, Taher A, Pathare A, et al. Plasma LPI in beta-thalassemia patients before and after treatment with deferasirox (Exjade (R), ICL670) [abstract]. <span class=\"ref-journal\">Blood</span>. 2005;<span class=\"ref-vol\">106</span>: 758a. Abstract 2697.</span></div><div class=\"ref-cit-blk half_rhythm\" id=\"ref17\">17. <span class=\"citation\">Rachmilewitz EA, Weizer-Stern O, Adamsky K, et al. Role of iron in inducing oxidative stress in thalassemia: can it be prevented by inhibition of absorption and by antioxidants? <span class=\"ref-journal\">Ann N Y Acad Sci</span>. 2005;<span class=\"ref-vol\">1054</span>: 118-123.  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/16339657\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=1895765&amp;issue-id=141776&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"ref18\">18. <span class=\"citation\">Glickstein H, El RB, Shvartsman M, Cabantchik ZI. Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells. <span class=\"ref-journal\">Blood</span>. 2005;<span class=\"ref-vol\">106</span>: 3242-3250.  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/16020512\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=1895765&amp;issue-id=141776&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"ref19\">19. <span class=\"citation\">Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. <span class=\"ref-journal\">Blood</span>. 1997;<span class=\"ref-vol\">89</span>: 739-761.  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/9028304\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=1895765&amp;issue-id=141776&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"ref20\">20. <span class=\"citation\">Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. <span class=\"ref-journal\">Eur Heart J</span>. 2001;<span class=\"ref-vol\">22</span>: 2171-2179.  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/11913479\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=1895765&amp;issue-id=141776&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"ref21\">21. <span class=\"citation\">Pennell DJ. T2* magnetic resonance and myocardial iron in thalassemia. <span class=\"ref-journal\">Ann N Y Acad Sci</span>. 2005;<span class=\"ref-vol\">1054</span>: 373-378.  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/16339685\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=1895765&amp;issue-id=141776&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"ref22\">22. <span class=\"citation\">Brittenham GM, Sheth S, Allen CJ, Farrell DE. Noninvasive methods for quantitative assessment of transfusional iron overload in sickle cell disease. <span class=\"ref-journal\">Semin Hematol</span>. 2001;<span class=\"ref-vol\">38</span>: 37-56.  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/11206960\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=1895765&amp;issue-id=141776&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"ref23\">23. <span class=\"citation\">Sheth S. SQUID biosusceptometry in the measurement of hepatic iron. <span class=\"ref-journal\">Pediatr Radiol</span>. 2003;<span class=\"ref-vol\">33</span>: 373-377.  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/12768253\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=1895765&amp;issue-id=141776&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"ref24\">24. <span class=\"citation\">St Pierre TG, Clark PR, Chua-anusorn W, et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. <span class=\"ref-journal\">Blood</span>. 2005;<span class=\"ref-vol\">105</span>: 855-861.  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/15256427\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=1895765&amp;issue-id=141776&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"ref25\">25. <span class=\"citation\">Brittenham GM, Nathan DG, Olivieri NF, Pippard MJ, Weatherall DJ. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility. <span class=\"ref-journal\">Lancet</span>. 2003;<span class=\"ref-vol\">361</span>: 183; author reply 183-184.  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/12531619\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=1895765&amp;issue-id=141776&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"ref26\">26. <span class=\"citation\">Wood JC, Otto-Duessel M, Aguilar M, et al. Cardiac iron determines cardiac T2*, T2, and T1 in the gerbil model of iron cardiomyopathy. <span class=\"ref-journal\">Circulation</span>. 2005;<span class=\"ref-vol\">112</span>: 535-543. <span class=\"nowrap ref pmc\">[<a class=\"int-reflink\" href=\"/pmc/articles/PMC2896311/\">PMC free article</a>]</span>  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/16027257\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=1895765&amp;issue-id=141776&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"ref27\">27. <span class=\"citation\">Wood JC, Tyszka JM, Carson S, Nelson MD, Coates TD. Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease. <span class=\"ref-journal\">Blood</span>. 2004;<span class=\"ref-vol\">103</span>: 1934-1936.  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/14630822\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=1895765&amp;issue-id=141776&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"ref28\">28. <span class=\"citation\">Westwood M, Anderson LJ, Firmin DN, et al. A single breath-hold multiecho T2* cardiovascular magnetic resonance technique for diagnosis of myocardial iron overload. <span class=\"ref-journal\">J Magn Reson Imaging</span>. 2003;<span class=\"ref-vol\">18</span>: 33-39.  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/12815637\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=1895765&amp;issue-id=141776&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"ref29\">29. <span class=\"citation\">Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. <span class=\"ref-journal\">Lancet</span>. 2002;<span class=\"ref-vol\">360</span>: 516-520.  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/12241655\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=1895765&amp;issue-id=141776&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"ref30\">30. <span class=\"citation\">Greenberg P, Dine G, Ganser A, et al. Deferasirox (Exjade (R), ICL670) demonstrates dose-related effects on body iron levels related to transfusional iron intake in transfusion-dependent anemia [abstract]. <span class=\"ref-journal\">Blood</span>. 2005;<span class=\"ref-vol\">106</span>: 757a. Abstract 2694.</span></div><div class=\"ref-cit-blk half_rhythm\" id=\"ref31\">31. <span class=\"citation\">Cohen A, Masera G, Zoumbos N, et al. Effect of iron intake on control of body iron in patients with thalassemia major treated with deferasirox (Exjade((R)), ICL670) [abstract]. <span class=\"ref-journal\">Blood</span>. 2005;<span class=\"ref-vol\">106</span>: 242a. Abstract 822.</span></div><div class=\"ref-cit-blk half_rhythm\" id=\"ref32\">32. <span class=\"citation\">Piga A, Gaglioti C, Fogliacco E, Tricta F. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. <span class=\"ref-journal\">Haematologica</span>. 2003;<span class=\"ref-vol\">88</span>: 489-496.  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/12745268\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=1895765&amp;issue-id=141776&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"ref33\">33. <span class=\"citation\">Gomber S, Saxena R, Madan N. Comparative efficacy of desferrioxamine, deferiprone and in combination on iron chelation in thalassemic children. <span class=\"ref-journal\">Indian Pediatr</span>. 2004;<span class=\"ref-vol\">41</span>: 21-27.  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/14767084\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=1895765&amp;issue-id=141776&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"ref34\">34. <span class=\"citation\">Delea TE, Sofrygin O, Thomas SK, Baladi JF, Phatak PD, Coates TD. Cost-effectiveness of once-daily oral chelation therapy with deferasirox (Exjade (R), ICL670) versus infusional deferoxamine in transfusion-dependent thalassemic patients [abstract]. <span class=\"ref-journal\">Blood</span>. 2005;<span class=\"ref-vol\">106</span>: 389a. Abstract 1341.  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/17402805\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=1895765&amp;issue-id=141776&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"ref35\">35. <span class=\"citation\">Renfroe JL, Forbes P, Braunstein J, Neufeld EJ. Relationship of transfusion and iron-related complications to cost of care in thalassemia [abstract]. <span class=\"ref-journal\">Blood</span>. 2005;<span class=\"ref-vol\">106</span>: 631a. Abstract 2240.</span></div><div class=\"ref-cit-blk half_rhythm\" id=\"ref36\">36. <span class=\"citation\">Delea TE, Thomas SK, Baladi JF, Phatak PD. Cost-effectiveness analysis of oral iron chelation therapy with deferasirox (Exjade (R), ICL670) versus infusional chelation therapy with deferoxamine in patients with transfusion-dependent myelodysplastic syndrome [abstract]. <span class=\"ref-journal\">Blood</span>. 2005;<span class=\"ref-vol\">106</span>: 484b-485b. Abstract 5585.</span></div><div class=\"ref-cit-blk half_rhythm\" id=\"ref37\">37. <span class=\"citation\">Vichinsky E, Fischer R, Fung E, et al. A randomized, controlled phase II trial in sickle cell disease patients with chronic iron overload demonstrates that the once-daily oral iron chelator deferasirox (Exjade((R)) ICL670) is well tolerated and reduces iron burden [abstract]. <span class=\"ref-journal\">Blood</span>. 2005;<span class=\"ref-vol\">106</span>: 95a. Abstract 313.</span></div><div class=\"ref-cit-blk half_rhythm\" id=\"ref38\">38. <span class=\"citation\">Porter JB, Tanner MA, Pennell DJ, Eleftheriou P. Improved myocardial T2*in transfusion dependent anemias receiving ICL670 (Deferasirox) [abstract]. <span class=\"ref-journal\">Blood</span>. 2005;<span class=\"ref-vol\">106</span>: 1003a. Abstract 3600.</span></div><div class=\"ref-cit-blk half_rhythm\" id=\"ref39\">39. <span class=\"citation\">Porter J, Borgna-Pignatti C, Baccarani M, et al. Iron chelation efficiency of deferasirox (Exjade (R), ICL670) in patients with transfusional hemosiderosis [abstract]. <span class=\"ref-journal\">Blood</span>. 2005;<span class=\"ref-vol\">106</span>: 755a. Abstract 2690.</span></div><div class=\"ref-cit-blk half_rhythm\" id=\"ref40\">40. <span class=\"citation\">Mourad FH, Hoffbrand AV, Sheikh-Taha M, Koussa S, Khoriaty AI, Taher A. Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients. <span class=\"ref-journal\">Br J Haematol</span>. 2003;<span class=\"ref-vol\">121</span>: 187-189.  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/12670352\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=1895765&amp;issue-id=141776&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"ref41\">41. <span class=\"citation\">Link G, Konijn AM, Breuer W, Cabantchik ZI, Hershko C. Exploring the &#x0201c;iron shuttle&#x0201d; hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture. <span class=\"ref-journal\">J Lab Clin Med</span>. 2001;<span class=\"ref-vol\">138</span>: 130-138.  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/11477380\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=1895765&amp;issue-id=141776&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"ref42\">42. <span class=\"citation\">Grady RW, Giardina PJ. Iron chelation: rationale for combination therapy. In: Dadman DG, Bergeron RJ, Brittenham GM, eds. <span class=\"ref-journal\">Iron Chelators: New Development Strategies</span>. Ponte Vedra Beach, FL: Saratoga; 2000: 293-310.</span></div></div></div></div><!--post-content--><hr class=\"whole_rhythm no_bottom_margin\" /><div class=\"courtesy-note no_margin small\">Articles from <span class=\"acknowledgment-journal-title\">Blood</span> are provided here courtesy of <strong>American Society of Hematology</strong></div></div>\n            \n            \n        \n            \n        </div>\n        <!-- Book content -->\n    </div>\n    \n    <div id=\"rightcolumn\" class=\"four_col col last\">\n        <!-- Custom content above discovery portlets -->\n        <div class=\"col6\">\n            \n        </div>\n        \n        <div xmlns:np=\"http://ncbi.gov/portal/XSLT/namespace\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\"><div class=\"format-menu\"><h2>Formats:</h2><ul><li class=\"selected\">Article</li> | <li><a href=\"/pmc/articles/PMC1895765/?report=reader\">PubReader</a></li> | <li class=\"epub-link\"><a href=\"/pmc/articles/PMC1895765/epub/\">ePub (beta)</a></li> | <li><a href=\"/pmc/articles/PMC1895765/?report=printable\">Printer Friendly</a></li> | <li><a href=\"#\" data-citationid=\"PMC1895765\" class=\"citationexporter ctxp\">Citation</a></li></ul></div></div><div xmlns:np=\"http://ncbi.gov/portal/XSLT/namespace\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\" class=\"share-buttons\"><h2>Share</h2><ul><li class=\"facebook\"><a href=\"https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1895765%2F\"><img src=\"//static.pubmed.gov/portal/portal3rc.fcgi/4132802/img/4047626\" alt=\"Share on Facebook\" />\n                             Facebook\n                        </a></li><li class=\"twitter\"><a href=\"https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1895765%2F&amp;text=Oral%20chelators%20deferasirox%20and%20deferiprone%20for%20transfusional%20iron%20overload%20in%20thalassemia%20major%3A%20new%20data%2C%20new%20questions\"><img src=\"//static.pubmed.gov/portal/portal3rc.fcgi/4132802/img/4047627\" alt=\"Share on Twitter\" />\n                             Twitter\n                        </a></li><li class=\"gplus\"><a href=\"https://plus.google.com/share?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1895765%2F\"><img src=\"//static.pubmed.gov/portal/portal3rc.fcgi/4132802/img/4047628\" alt=\"Share on Google Plus\" />\n                             Google+\n                        </a></li></ul></div>\n        \n        <div id=\"ajax-portlets\" data-pmid=\"16627763\" data-aiid=\"1895765\" data-aid=\"1895765\" data-iid=\"141776\" data-domainid=\"446\" data-domain=\"blood\" data-accid=\"PMC1895765\" data-md5=\"f81fcb63df1b2397ed7b9057655d868e\"></div>\n                \n        <!-- Custom content below discovery portlets -->\n        <div class=\"col7\">\n            \n        </div>\n    </div>\n</div>\n\n<!-- Custom content after all -->\n<div class=\"col8\">\n    \n</div>\n<div class=\"col9\">\n    \n</div>\n\n<script src=\"/corehtml/pmc/js/jquery.scrollTo-1.4.2.js\"></script>\n<script>\n    (function($){\n        $('.skiplink').each(function(i, item){\n            var href = $($(item).attr('href'));\n            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus\n            $(item).on('click', function(event){\n                event.preventDefault();\n                $.scrollTo(href, 0, {\n                    onAfter: function(){\n                        href.focus();\n                    }\n                });\n            });\n        });\n    })(jQuery);\n</script>\n\n\n\n<div id=\"body-link-poppers\"></div>\n                        </div>\n                        <div class=\"bottom\">\n                            \n                            <div id=\"NCBIFooter_dynamic\">\n    <div class=\"breadcrumbs\">You are here: \n            <span id=\"breadcrumb_text\"><a href=\"/guide/\">NCBI</a> &gt; <a href=\"https://www.ncbi.nlm.nih.gov/guide/literature/\">Literature</a> &gt; <a href=\"https://www.ncbi.nlm.nih.gov/pmc/\">PubMed Central (PMC)</a></span></div>\n    <a id=\"help-desk-link\" class=\"help_desk jig-ncbihelpwindow\" target=\"_blank\" href=\"/sites/ehelp?&amp;Ncbi_App=pmc&amp;Db=pmc&amp;Page=literature&amp;Snapshot=/projects/PMC/PMCViewer@4.39&amp;Time=2016-11-05T22:45:36-04:00&amp;Host=ptpmc201\">Write to the Help Desk</a>\n    \n</div>\n\n                            <div class=\"footer\" id=\"footer\">\n    \n    <div class=\"subfooter\"> </div><script type=\"text/javascript\" src=\"/portal/portal3rc.fcgi/static/js/preloaderWidget.js\"> </script>\n    <div id=\"external-disclaimer\" class=\"offscreen_noflow\">\n        External link. Please review our <a href=\"https://www.nlm.nih.gov/privacy.html\">privacy policy</a>.\n    </div>    \n    <div id=\"ncbifooter\" class=\"contact_info\">      \n        <div id=\"footer-contents-right\">\n            <div id=\"nlm_thumb_logo\">\n                <a href=\"https://www.nlm.nih.gov\" title=\"NLM\">NLM</a>\n            </div>\n            <div id=\"nih_thumb_logo\">\n                <a href=\"https://www.nih.gov\" title=\"NIH\">NIH</a>\n            </div>\n            <div id=\"hhs_thumb_logo\">\n                <a href=\"https://www.hhs.gov\" title=\"DHHS\">DHHS</a>\n            </div>\n            <div id=\"usagov_thumb_logo\">\n                <a href=\"https://www.usa.gov\" title=\"USA.gov\">USA.gov</a>\n            </div>         \n        </div>\n        \n        <div id=\"footer-contents-left\">\n            <p class=\"address vcard\">\n                <span class=\"url\">\n                    <a class=\"fn url newdomain\" href=\"https://www.ncbi.nlm.nih.gov\">National Center for\n                        Biotechnology Information</a>,\n                </span> <span class=\"org url newdomain\"><a href=\"https://www.nlm.nih.gov/\">U.S. National Library of Medicine</a></span>\n                <span class=\"adr\">\n                    <span class=\"street-address\">8600 Rockville Pike</span>, <span class=\"locality\">Bethesda</span>\n                    <span class=\"region\">MD</span>, <span class=\"postal-code\">20894</span>\n                    <span class=\"country-name\">USA</span>\n                </span>\n            </p>\n            \n            <a href=\"/home/about/policies.shtml\">Policies and Guidelines</a> | <a href=\"/home/about/contact.shtml\">Contact</a>\n        </div>\n    </div>\n    <script type=\"text/javascript\" src=\"/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1\"> </script>    \n    <script type=\"text/javascript\" src=\"/portal/portal3rc.fcgi/static/js/hfjs2.js\"> </script>\n</div>\n                        </div>\n                    </div>\n                    <!--/.page-->\n                </div>\n                <!--/.wrap-->\n            </div><!-- /.twelve_col -->\n        </div>\n        <!-- /.grid -->\n\n        <span class=\"PAFAppResources\"></span>\n        \n        <!-- BESelector tab -->\n        \n        \n        \n        <noscript><img alt=\"statistics\" src=\"/stat?jsdisabled=true&amp;ncbi_db=pmc&amp;ncbi_pdid=article&amp;ncbi_acc=&amp;ncbi_domain=blood&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/articles/PMC1895765/&amp;ncbi_app=pmc\" /></noscript>\n        \n        \n        <!-- usually for JS scripts at page bottom -->\n        <!--<component id=\"PageFixtures\" label=\"styles\"></component>-->\n    \n\n<!-- F4FB116881E994F1_0062SID /projects/PMC/PMCViewer@4.39 ptpmc201 v4.1.r508797 Mon, Aug 01 2016 12:51:16 -->\n\n<script type=\"text/javascript\" src=\"//static.pubmed.gov/portal/portal3rc.fcgi/4132802/js/3879255/4121861/3818874/3821238/4117325/4087685/4072593/4076480/3921943/4105668/4065628.js\" snapshot=\"pmc\"></script></body>\n</html>"}